Acumen Pharmaceuticals Inc (NASDAQ: ABOS) is -50.78% lower on its value in year-to-date trading and has touched a low of $1.72 and a high of $5.09 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ABOS stock was last observed hovering at around $1.79 in the last trading session, with the day’s gains setting it 0.1%.
Currently trading at $1.89, the stock is -8.30% and -23.05% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.68 million and changing 5.59% at the moment leaves the stock -33.98% off its SMA200. ABOS registered -48.92% loss for a year compared to 6-month gain of -19.92%. The firm has a 50-day simple moving average (SMA 50) of $2.4649 and a 200-day simple moving average (SMA200) of $2.873725.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -19.92% gain in the last 1 month and extending the period to 3 months gives it a -22.22%, and is 5.59% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.62% over the week and 6.91% over the month.
Acumen Pharmaceuticals Inc (ABOS) has around 52 employees, a market worth around $113.55M and $0.00M in sales. Distance from 52-week low is 10.20% and -62.87% from its 52-week high. The company has generated returns on investments over the last 12 months (-33.06%).
The EPS is expected to shrink by -46.30% this year
108.0 institutions hold shares in Acumen Pharmaceuticals Inc (ABOS), with institutional investors hold 88.39% of the company’s shares. The shares outstanding are 60.08M, and float is at 45.03M with Short Float at 3.17%. Institutions hold 78.46% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 14.93 million shares valued at $36.14 million. The investor’s holdings represent 24.965 of the ABOS Shares outstanding. As of 2024-06-30, the second largest holder is SANDS CAPITAL VENTURES, LLC with 3.42 million shares valued at $8.27 million to account for 5.713 of the shares outstanding. The other top investors are FRANKLIN RESOURCES INC which holds 3.37 million shares representing 5.6303 and valued at over $8.15 million, while ROCK SPRINGS CAPITAL MANAGEMENT LP holds 3.8455 of the shares totaling 2.3 million with a market value of $5.57 million.
Acumen Pharmaceuticals Inc (ABOS) Insider Activity
The most recent transaction is an insider sale by OConnell Daniel Joseph, the company’s President and CEO. SEC filings show that OConnell Daniel Joseph sold 15,200 shares of the company’s common stock on Jan 19 ’24 at a price of $3.47 per share for a total of $52753.0. Following the sale, the insider now owns 0.5 million shares.
Acumen Pharmaceuticals Inc disclosed in a document filed with the SEC on Jan 19 ’24 that Meisner Derek M (Chief Legal Officer & Corp Sec) sold a total of 8,933 shares of the company’s common stock. The trade occurred on Jan 19 ’24 and was made at $3.48 per share for $31048.0. Following the transaction, the insider now directly holds 0.11 million shares of the ABOS stock.
Still, SEC filings show that on Jan 18 ’24, Zuga Matt (CFO & Chief Business Officer) disposed off 4,242 shares at an average price of $3.71 for $15717.0. The insider now directly holds 211,445 shares of Acumen Pharmaceuticals Inc (ABOS).
